Generic Name and Formulations:
Potassium (as chloride) 10mEq; sust-rel tabs.
- Diabetes May Decrease Ability to Feel Acid Regurgitation
- More Adverse Events and Higher Costs for Patients With RA on High-Dose Glucocorticoids
- Bydureon Single Dose Trays to Be Discontinued
Indications for K-TAB:
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block.
Do not chew or crush. Take with meals. Prophylaxis: 20mEq daily. Treatment: 40–100mEq daily in divided doses; max 20mEq/dose.
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Esophageal compression due to enlarged left atrium. Decreased GI motility.
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets.
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Esophageal and GI ulceration, bleeding, obstruction, perforation.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks